BridgeBio Pharma (NASDAQ:BBIO) CFO Thomas Trimarchi Sells 16,934 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Thomas Trimarchi sold 16,934 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $66.46, for a total value of $1,125,433.64. Following the sale, the chief financial officer owned 382,830 shares of the company’s stock, valued at approximately $25,442,881.80. This represents a 4.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Thomas Trimarchi also recently made the following trade(s):

• On Thursday, August 21st, Thomas Trimarchi sold 42,237 shares of BridgeBio Pharma stock. The shares were sold at an average price of $49.48, for a total transaction of $2,089,886.76.

BridgeBio Pharma Stock Down 2.0%

NASDAQ BBIO opened at $65.59 on Wednesday. The stock has a market capitalization of $12.64 billion, a PE ratio of -15.69 and a beta of 1.39. BridgeBio Pharma, Inc. has a 12-month low of $21.72 and a 12-month high of $69.48. The company has a 50 day moving average price of $56.98 and a two-hundred day moving average price of $48.09.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Wednesday, October 29th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). The firm had revenue of $120.70 million for the quarter, compared to analyst estimates of $107.71 million. The company’s quarterly revenue was up 4318.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.86) EPS. As a group, equities analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

Institutional Trading of BridgeBio Pharma

Hedge funds have recently added to or reduced their stakes in the business. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in BridgeBio Pharma in the 2nd quarter worth approximately $25,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of BridgeBio Pharma in the third quarter worth $31,000. Harvest Fund Management Co. Ltd bought a new position in BridgeBio Pharma during the third quarter worth $34,000. Jones Financial Companies Lllp acquired a new position in BridgeBio Pharma during the 1st quarter valued at $35,000. Finally, First Horizon Corp bought a new stake in BridgeBio Pharma in the 3rd quarter valued at $36,000. Institutional investors own 99.85% of the company’s stock.

Analyst Ratings Changes

BBIO has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price target on shares of BridgeBio Pharma in a research report on Monday, November 3rd. TD Cowen raised their price objective on BridgeBio Pharma from $60.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Scotiabank upped their target price on BridgeBio Pharma from $55.00 to $57.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, August 6th. JPMorgan Chase & Co. increased their price target on BridgeBio Pharma from $76.00 to $77.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Finally, Cantor Fitzgerald boosted their price objective on shares of BridgeBio Pharma from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Twenty equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $74.37.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.